Developer docs
API playgroundTry for free, no card

Search company profiles

Adicet Bio

Full company profile

uuid0000bhk

Namestring
Adicet Bio
Legal namestring
Adicet Bio, Inc.
Websiteurl
adicetbio.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Adicet Bio, Inc. is a clinical-stage biotechnology company founded in 2014 and listed on NASDAQ under the ticker ACET. The company develops allogeneic ("off-the-shelf") gamma delta 1 CAR T cell therapies for B-cell mediated autoimmune diseases and cancer, leveraging the natural tissue-homing properties of gamma delta 1 T cells and engineered chimeric antigen receptors to enable immediate, patient-independent dosing without autologous manufacturing delays.

Its pipeline is anchored by prula-cel (formerly ADI-001), a CD20-directed allogeneic gamma delta CAR T candidate in Phase 1 development across multiple autoimmune indications — including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis — and which has received FDA Fast Track Designation in three of these indications. Supporting programs include ADI-212 (armored PSMA-directed gamma delta CAR T for metastatic castration-resistant prostate cancer, IND planned for early 2026), ADI-270 (CD70-directed for solid and hematologic tumors), and ADI-925 (Chimeric Adapter gamma delta T cells targeting NKG2D ligand-expressing cancers). A May 2025 license agreement with CRISPR Therapeutics provides gene-editing capability for next-generation candidates, with a 50/50 cost-and-profit opt-in retained by CRISPR.

The company is pre-revenue with no commercialized products and no disclosed payer or partnership economics. It is financed through public equity ($100M in 2021, $98M in 2024, $80M in 2025), with operations spanning R&D in Redwood City (California), corporate headquarters in Boston (Massachusetts), and an office in Shanghai (China), and reports 101–250 employees. A 1-for-16 reverse stock split was executed on December 30, 2025 to maintain Nasdaq listing compliance, and Ra Capital Management is the largest disclosed shareholder at roughly 6.75%. Revenue generation is contingent on regulatory approval of one or more candidates, with a pivotal trial for prula-cel planned for Q2 2026 following an early-2026 FDA meeting.

Short descriptiontext

Adicet Bio is a clinical-stage, NASDAQ-listed biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies targeting B-cell mediated autoimmune diseases and cancer, with lead candidate prula-cel in Phase 1 across multiple autoimmune indications and supporting oncology programs in earlier development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, gamma delta CAR T, autoimmune disease therapy, oncology immunotherapy, off-the-shelf cell therapy
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / Immunotherapy Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical/Biotech Revenue
TypeOne Time License
Description

Adicet Bio is a clinical-stage biotechnology company and is pre-revenue. The company is developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Once therapies receive regulatory approval, revenue would be generated through product sales.

adicetbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies for autoimmune diseases and cancer. Its lead candidate prula-cel (ADI-001) is a CD20-targeted allogeneic gamma delta CAR T cell therapy in Phase 1 development for lupus nephritis, SLE, systemic sclerosis, rheumatoid arthritis, and other autoimmune indications. The pipeline also includes ADI-212 (PSMA for prostate cancer), ADI-270 (CD70 for solid and hematologic tumors), and ADI-925 (NKG2D ligand targeting).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Positive preliminary safety and efficacy data from Phase 1 trial of ADI-001 in lupus nephritis and SLE patients
+2 more records
Product overview1 text field

Adicet Bio is a clinical stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's proprietary platform engineers gamma delta 1 T cells with chimeric antigen receptors (CARs) to enable off-the-shelf treatments. The lead product is prulacabtagene leucel (prula-cel, formerly ADI-001), a CD20-targeted CAR gamma delta T cell therapy in Phase 1 development for multiple autoimmune conditions. The pipeline also includes ADI-212 (PSMA-targeted for prostate cancer), ADI-270 (CD70-targeted for solid and hematologic tumors), and ADI-925 (NKG2D ligand-targeted), with additional programs in discovery and preclinical stages anticipated to yield new INDs every 12-18 months.

Product and service4 records
1Prulacabtagene leucel (prula-cel, formerly ADI-001)
CategoryCell therapy / Immunotherapy
Description

First-in-class investigational allogeneic gamma delta CAR T cell therapy targeting CD20, in Phase 1 development for autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis.

2ADI-212 (PSMA CAR Gamma Delta T Cell Program)
CategoryCell therapy / Oncology immunotherapy
Description

Armored allogeneic CAR gamma delta T cell therapy targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC), featuring a potent CAR construct with three mechanisms of action designed to address tumor heterogeneity.

3ADI-270
CategoryCell therapy / Oncology immunotherapy
Description

Armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies.

4ADI-925
CategoryCell therapy / Oncology immunotherapy
Description

Allogeneic off-the-shelf Chimeric Adapter (CAd) gamma delta T cell therapy targeting NKG2D ligand-expressing cancers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-05-26
Description

License agreement with CRISPR Therapeutics for gene-editing technology. CRISPR has opt-in right to participate in a 50/50 cost and profit split for programs utilizing their technology. This partnership enables Adicet to leverage CRISPR's gene-editing capabilities in developing next-generation allogeneic gamma delta T cell therapies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing CAR-T cell therapies, including CD19-CAR-T candidates (e.g., CABA-201) for autoimmune diseases such as lupus and myositis. Directly comparable to Adicet's prula-cel in autoimmune CAR-T space with similar patient populations and clinical stage.

TypeDirect peer
Description

Clinical-stage cell therapy company developing CD19 CAR-T therapies for autoimmune diseases including lupus nephritis and other B-cell-mediated conditions. Direct competitor to Adicet's prula-cel with overlapping autoimmune CAR-T focus and Phase 1/2 development stage.

TypeDirect peer
Description

Pioneering allogeneic CAR-T cell therapy company with multiple clinical-stage candidates for hematologic and solid tumors. Directly comparable to Adicet as a competing allogeneic CAR-T platform with similar off-the-shelf manufacturing approach.

TypeDirect peer
Description

Allogeneic T-cell immunotherapy company developing off-the-shelf therapies for cancer and autoimmune diseases. Highly comparable platform approach to Adicet with allogeneic T-cell platform technology; CSO Blake Aftab previously led preclinical science at Atara.

TypeDirect peer
Description

Leading gene-editing company developing CRISPR/Cas9-based therapies including allogeneic CAR-T candidates (CTX112) for autoimmune and oncology indications. Both partner and competitor to Adicet through gene-editing license arrangement.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Comparable allogeneic, off-the-shelf cell therapy platform with similar manufacturing scalability approach to Adicet's gamma delta platform.

TypeDirect peer
Description

Clinical-stage biotechnology company developing allogeneic, iPSC-derived immune cell therapies for cancer and autoimmune diseases. Comparable off-the-shelf cell therapy platform with overlapping oncology and autoimmune indications.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using CRISPR gene-editing technology for hematologic malignancies and autoimmune diseases. Comparable allogeneic CAR-T platform with similar technology base.

TypeEmerging player
Description

Clinical-stage biotechnology company developing engineered cell therapies with hypoimmune technology for cancer and autoimmune diseases. Comparable cell therapy focus with novel allogeneic platform approach and autoimmune indication overlap.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Global biopharmaceutical company with approved autologous CAR-T therapies (Breyanzi, Abecma) and broad autoimmune portfolio. Represents incumbent CAR-T commercialization expertise and potential strategic acquirer or partner for allogeneic CAR-T developers like Adicet.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adicet Bio

Cell Therapy / Immunotherapy Biopharmaceuticalsadicetbio.com

Adicet Bio is a clinical-stage, NASDAQ-listed biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies targeting B-cell mediated autoimmune diseases and cancer, with lead candidate prula-cel in Phase 1 across multiple autoimmune indications and supporting oncology programs in earlier development.

What Adicet Bio does

Adicet Bio, Inc. is a clinical-stage biotechnology company founded in 2014 and listed on NASDAQ under the ticker ACET. The company develops allogeneic ("off-the-shelf") gamma delta 1 CAR T cell therapies for B-cell mediated autoimmune diseases and cancer, leveraging the natural tissue-homing properties of gamma delta 1 T cells and engineered chimeric antigen receptors to enable immediate, patient-independent dosing without autologous manufacturing delays.

Its pipeline is anchored by prula-cel (formerly ADI-001), a CD20-directed allogeneic gamma delta CAR T candidate in Phase 1 development across multiple autoimmune indications — including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis — and which has received FDA Fast Track Designation in three of these indications. Supporting programs include ADI-212 (armored PSMA-directed gamma delta CAR T for metastatic castration-resistant prostate cancer, IND planned for early 2026), ADI-270 (CD70-directed for solid and hematologic tumors), and ADI-925 (Chimeric Adapter gamma delta T cells targeting NKG2D ligand-expressing cancers). A May 2025 license agreement with CRISPR Therapeutics provides gene-editing capability for next-generation candidates, with a 50/50 cost-and-profit opt-in retained by CRISPR.

The company is pre-revenue with no commercialized products and no disclosed payer or partnership economics. It is financed through public equity ($100M in 2021, $98M in 2024, $80M in 2025), with operations spanning R&D in Redwood City (California), corporate headquarters in Boston (Massachusetts), and an office in Shanghai (China), and reports 101–250 employees. A 1-for-16 reverse stock split was executed on December 30, 2025 to maintain Nasdaq listing compliance, and Ra Capital Management is the largest disclosed shareholder at roughly 6.75%. Revenue generation is contingent on regulatory approval of one or more candidates, with a pivotal trial for prula-cel planned for Q2 2026 following an early-2026 FDA meeting.

Adicet Bio firmographics

Firmographics
Name
Adicet Bio
Legal name
Adicet Bio, Inc.
Website
https://adicetbio.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Adicet Bio is a clinical-stage, NASDAQ-listed biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies targeting B-cell mediated autoimmune diseases and cancer, with lead candidate prula-cel in Phase 1 across multiple autoimmune indications and supporting oncology programs in earlier development.
Ownership category
akta.pro rank

Adicet Bio industry classification

Industry
Product category
Cell Therapy / Immunotherapy Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Allogeneic cell therapy
  • Gamma delta CAR T
  • Autoimmune disease therapy
  • Oncology immunotherapy
  • Off-the-shelf cell therapy

Where Adicet Bio is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Adicet Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical/Biotech Revenue: Adicet Bio is a clinical-stage biotechnology company and is pre-revenue. The company is developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Once therapies receive regulatory approval, revenue would be generated through product sales.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Adicet Bio product offering

Product offering

Core offering

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies for autoimmune diseases and cancer. Its lead candidate prula-cel (ADI-001) is a CD20-targeted allogeneic gamma delta CAR T cell therapy in Phase 1 development for lupus nephritis, SLE, systemic sclerosis, rheumatoid arthritis, and other autoimmune indications. The pipeline also includes ADI-212 (PSMA for prostate cancer), ADI-270 (CD70 for solid and hematologic tumors), and ADI-925 (NKG2D ligand targeting).

Product overview

Adicet Bio is a clinical stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's proprietary platform engineers gamma delta 1 T cells with chimeric antigen receptors (CARs) to enable off-the-shelf treatments. The lead product is prulacabtagene leucel (prula-cel, formerly ADI-001), a CD20-targeted CAR gamma delta T cell therapy in Phase 1 development for multiple autoimmune conditions. The pipeline also includes ADI-212 (PSMA-targeted for prostate cancer), ADI-270 (CD70-targeted for solid and hematologic tumors), and ADI-925 (NKG2D ligand-targeted), with additional programs in discovery and preclinical stages anticipated to yield new INDs every 12-18 months.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prulacabtagene leucel (prula-cel, formerly ADI-001) First-in-class investigational allogeneic gamma delta CAR T cell therapy targeting CD20, in Phase 1 development for autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA-associated vasculitis, and rheumatoid arthritis.
  • ADI-212 (PSMA CAR Gamma Delta T Cell Program) Armored allogeneic CAR gamma delta T cell therapy targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC), featuring a potent CAR construct with three mechanisms of action designed to address tumor heterogeneity.
  • ADI-270 Armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies.
  • ADI-925 Allogeneic off-the-shelf Chimeric Adapter (CAd) gamma delta T cell therapy targeting NKG2D ligand-expressing cancers.

Quantifiable outcome

  • Positive preliminary safety and efficacy data from Phase 1 trial of ADI-001 in lupus nephritis and SLE patients
  • +2 more outcomes

Companies that use Adicet Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Adicet Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Adicet Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CRISPR TherapeuticscoreTechnology or Integration · 26 May 2025License agreement with CRISPR Therapeutics for gene-editing technology. CRISPR has opt-in right to participate in a 50/50 cost and profit split for programs utilizing their technology. This partnership enables Adicet to leverage CRISPR's gene-editing capabilities in developing next-generation allogeneic gamma delta T cell therapies.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Adicet Bio competitors and assessment

Company assessment

Direct peers

  • Cabaletta Bio: Clinical-stage biotechnology company developing CAR-T cell therapies, including CD19-CAR-T candidates (e.g., CABA-201) for autoimmune diseases such as lupus and myositis. Directly comparable to Adicet's prula-cel in autoimmune CAR-T space with similar patient populations and clinical stage.
  • Kyverna Therapeutics: Clinical-stage cell therapy company developing CD19 CAR-T therapies for autoimmune diseases including lupus nephritis and other B-cell-mediated conditions. Direct competitor to Adicet's prula-cel with overlapping autoimmune CAR-T focus and Phase 1/2 development stage.
  • Allogene Therapeutics: Pioneering allogeneic CAR-T cell therapy company with multiple clinical-stage candidates for hematologic and solid tumors. Directly comparable to Adicet as a competing allogeneic CAR-T platform with similar off-the-shelf manufacturing approach.
  • Atara Biotherapeutics: Allogeneic T-cell immunotherapy company developing off-the-shelf therapies for cancer and autoimmune diseases. Highly comparable platform approach to Adicet with allogeneic T-cell platform technology; CSO Blake Aftab previously led preclinical science at Atara.
  • CRISPR Therapeutics: Leading gene-editing company developing CRISPR/Cas9-based therapies including allogeneic CAR-T candidates (CTX112) for autoimmune and oncology indications. Both partner and competitor to Adicet through gene-editing license arrangement.
  • Fate Therapeutics: Clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Comparable allogeneic, off-the-shelf cell therapy platform with similar manufacturing scalability approach to Adicet's gamma delta platform.
  • Century Therapeutics: Clinical-stage biotechnology company developing allogeneic, iPSC-derived immune cell therapies for cancer and autoimmune diseases. Comparable off-the-shelf cell therapy platform with overlapping oncology and autoimmune indications.
  • Caribou Biosciences: Clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using CRISPR gene-editing technology for hematologic malignancies and autoimmune diseases. Comparable allogeneic CAR-T platform with similar technology base.

Emerging players

  • Sana Biotechnology: Clinical-stage biotechnology company developing engineered cell therapies with hypoimmune technology for cancer and autoimmune diseases. Comparable cell therapy focus with novel allogeneic platform approach and autoimmune indication overlap.

Broad incumbents

  • Bristol Myers Squibb: Global biopharmaceutical company with approved autologous CAR-T therapies (Breyanzi, Abecma) and broad autoimmune portfolio. Represents incumbent CAR-T commercialization expertise and potential strategic acquirer or partner for allogeneic CAR-T developers like Adicet.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Adicet Bio social profiles

Digital presence

Adicet Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adicet Bio leadership team

Management profile

Number of profiles

Profiles8 records

Adicet Bio funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adicet Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adicet Bio

What does Adicet Bio do?

Adicet Bio is a clinical-stage biotechnology company developing allogeneic gamma delta 1 CAR T cell therapies for autoimmune diseases and cancer. Its lead candidate prula-cel (ADI-001) is a CD20-targeted allogeneic gamma delta CAR T cell therapy in Phase 1 development for lupus nephritis, SLE, systemic sclerosis, rheumatoid arthritis, and other autoimmune indications. The pipeline also includes ADI-212 (PSMA for prostate cancer), ADI-270 (CD70 for solid and hematologic tumors), and ADI-925 (NKG2D ligand targeting).

Is Adicet Bio a public or private company?

Adicet Bio is a public company. It is classified as public and is currently operating.

When was Adicet Bio founded?

Adicet Bio was founded in 2014. It employs 101 to 250 people.

Where is Adicet Bio based?

Adicet Bio is headquartered in Redwood City, United States, in the North America region.

How does Adicet Bio make money?

One revenue line is on record: pharmaceutical/Biotech Revenue.

Who are Adicet Bio's main competitors?

Direct peers on record are Cabaletta Bio, Kyverna Therapeutics, Allogene Therapeutics, Atara Biotherapeutics, CRISPR Therapeutics, Fate Therapeutics, Century Therapeutics and Caribou Biosciences. Sana Biotechnology is listed as an emerging player. Bristol Myers Squibb is listed as a broad incumbent.

Does Adicet Bio have an API?

No public API is recorded for Adicet Bio.

What industry is Adicet Bio in?

Adicet Bio's product category is Cell Therapy / Immunotherapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAdicet Bio at Guggenheim conference: lupus data lifts pivotal hopesAdicet Bio presented lupus data at the Guggenheim conference, showing 50% complete renal response and 54% DORIS remission at 12 months in 22 patients, all off immunosuppressants. The FDA agreed on immunosuppressant-free complete renal response at 12 months as the primary endpoint, and the company expects a pivotal study in the near term.TradingViewGuggenheim maintains Adicet Bio at Buy, lowers price target to $55 from $90Guggenheim maintained Adicet Bio at Buy and lowered its price target to $55 from $90, a 38.9% decrease. The target implies an upside of 1783.6% from the Nov 5 close of $2.92.American Banking and Market NewsAdicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Adicet Bio from hold to sell, while other analysts have mixed ratings. The stock opened at $4.57, with a consensus rating of Moderate Buy and an average target price of $37.80. The company reported a loss of $1.99 per share for the quarter, missing estimates.Markets DailyAdicet Bio, Inc. (NASDAQ:ACET) Stock Short Interest Rises 78.5%Adicet Bio's short interest rose 78.5% to 485,466 shares as of September 30th. Analysts have a consensus 'Moderate Buy' rating with an average price target of $37.80. The company reported a Q2 loss of $1.99 per share, missing the consensus estimate.American Banking and Market NewsRecent Research Analysts’ Ratings Updates for Adicet Bio (ACET)Analysts have recently updated their ratings on Adicet Bio, with several firms reaffirming or raising price targets. HC Wainwright raised its target to $34, while others reaffirmed buy or outperform ratings. The company develops allogeneic gamma delta CAR T-cell therapies for cancer and autoimmune diseases.American Banking and Market NewsAdicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 MonthsAdicet Bio reported that its investigational prula-cel CAR-T therapy achieved 54% DORIS remission at 12 months in systemic lupus erythematosus patients, including 50% complete renal response among lupus nephritis patients. The remissions occurred while patients were off immunosuppressants and on ≤5 mg prednisone equivalent. The company plans a pivotal study in lupus nephritis patients, with interim data expected in 2028.The future of tradingAdicet Bio grants new-hire stock options for 725 shares at $7.14 each under inducement planAdicet Bio granted a new-hire non-qualified stock option award on Sept. 30, 2026, covering 725 shares at an exercise price of $7.14 per share, matching the Nasdaq closing price that day. The award is under the company's 2022 Inducement Plan, with vesting starting at 25% on the first anniversary and monthly over 36 months to year four.Seeking AlphaAdicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptAdicet Bio announced positive data for prula-cel and plans to advance it into a pivotal study for lupus nephritis. The company's CEO and medical officer will present the clinical data, with the chief scientific officer to discuss immune reset evidence.BioPharma DiveAn ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupusAdicet Bio's allogeneic CAR-T therapy prula-cel showed in a trial that 50% of lupus nephritis patients achieved a complete kidney response and 54% met remission criteria. The company reported no serious cytokine release syndrome or neurological side effects, and plans a pivotal study in the fourth quarter.AdvfnAdicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans AdvanceAdicet Bio reported Phase 1 data for prula-cel, showing 54% DORIS remission and 50% complete renal response in lupus patients. The company plans to start pivotal lupus nephritis study activities in Q4 2026, with a single-arm design and complete renal response as the primary endpoint.